Roche shuffles its executive committee - Breaking The News

Roche shuffles its executive committee

27 May

1 min read

EPA-EFE/STEFFEN SCHMIDT

F. Hoffmann-La Roche AG revealed on Monday in a press release the changes made to its enlarged Corporate Executive Committee.

Head of Roche Pharma Partnering James Sabry will retire after spending 14 years at the company, it was mentioned in the press release. Head of Group Business Development Boris Zaitra will be given a new role and act as head of Corporate Business Development starting July 1, 2024.

"James has been instrumental in forging important deals for our Pharma R&D pipeline that have led to numerous launches of new medicines. I am grateful for James`s contributions ... Leveraging external innovation has always been and continues to be a critical part of our business strategy. I am excited to have Boris Zaitra take on this new role," CEO Thomas Schinecker commented.

roche

Related Stocks

Roche Holding Gen.r.

Roche's Q1 sales up 6% to 15.4 billion Swiss francs

24 April

F. Hoffmann-La Roche AG said on Thursday its sales in the first quarter of fiscal 2025 reached 15.4 billion Swiss francs, climbing 7% in Swiss francs and 6% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 11.95 billion Swiss francs, while diagnostics division sales amounted to 3.49 Swiss francs, virtually unchanged from the same timeframe in 2024."We had a good start to the year with...

Roche to invest $50B in US pharmaceuticals

22 April

F. Hoffmann-La Roche AG announced on Tuesday that it will invest $50 billion in the United States over the next five years.Roche hopes to strengthen already established manufacturing and open new facilities, starting with Indiana, Pennsylvania, Massachusetts, and California. As part of the investment, the number of employees will increase by more than 12,000."Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today's announced...

Pharma stocks drop in Europe amid Trump tariff plans

9 April

Stocks of major European pharmaceutical companies, including French Sanofi, British GSK and AstraZeneca, as well as Swiss Roche and Novartis, saw a decline on Wednesday following US President Donald Trump's announcement of a "major tariff" on pharmaceuticals. Trump revealed that Washington would soon impose the tariff, prompting concerns among investors about the potential impact on the global market.At 10:18 am CET, Novartis AG nosedived...

Roche's 2024 sales up 7% to 60.5B Swiss francs

30 January

F. Hoffmann-La Roche AG said on Thursday its annual sales in 2024 reached 60.5 billion Swiss francs, climbing 3% in Swiss francs and 7% at constant exchange rates (CER) from the same period a year earlier. Sales in the pharmaceuticals division grew 8% at CER to 46.2 billion Swiss francs, while diagnostics division sales rose 4% at CER year on year to 14.3 billion Swiss francs.In the year, net income dropped 19% at CER to 9.2 billion Swiss francs...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.